Association of COVID-19 Vaccination Status with Nirmatrelvir/Ritonavir Utilization in Medicare Beneficiaries: A Retrospective Cohort Analysis

As COVID-19 vaccination recommendations continue to evolve, understanding how vaccination influences treatment use and overall health care costs remains an important consideration for Medicare populations. Nirmatrelvir/ritonavir is a first-line outpatient treatment for individuals at high risk of severe COVID-19, yet the relationship between vaccination status and treatment utilization is not fully understood. Evaluating utilization patterns across vaccination groups may provide insight into the clinical and financial impact of COVID-19 vaccination among Medicare beneficiaries.